Previously submitted to: Interactive Journal of Medical Research (no longer under consideration since May 04, 2023)
Date Submitted: Apr 25, 2023
Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.
Exenatide for obesity in children and adolescents: Systematic Review and Meta-analysis
ABSTRACT
Background:
There is no curative treatment for childhood obesity.
Objective:
We aimed to synthesize published randomized controlled trials (RCTs) evidence on the efficacy of exenatide in obese children and adolescents.
Methods:
We searched and investigated all relevant studies in the PubMed, Web of Science, Embase, and Cochrane Library databases. Inclusion criteria were RCTs of exenatide for the treatment of obesity in children and adolescents. Primary outcomes were body weight, body mass index (BMI), fasting plasma glucose (FPG) or HbA1c change. Secondary outcomes were the occurrence of adverse events, especially hypoglycemia. The Cochrane bias assessment tool was used to assess the risk of bias in RCTs.
Results:
Five studies met the inclusion criteria. In total,100children were allocated to exenatide therapy. Compared with controls, exenatide therapy reduced body weight and BMI by −0.6%(95% CI −0.93,-0.27），−1.11%(95% CI −1.91,-0.31）， respectively. Adverse effects include gastrointestinal symptoms, the majority of these cases were mild in severity.
Conclusions:
Exenatide is effective in treating obesity in children and adolescents. Clinical Trial: https://www.crd.york.ac.uk/prospero/, identifier CRD42023413706.
Citation
Request queued. Please wait while the file is being generated. It may take some time.
Copyright
© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.